{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-001953","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.682018+00:00","generated_at":"2026-05-16T11:10:38.919452+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium Pharma guides FY2026 revenue $805-825M; Jornay PM $190-200M; adj. EBITDA $455-475M","bullets":["Product revenue guidance $805-825M; Jornay PM net revenue $190-200M.","Adjusted EBITDA guidance $455-475M, flat versus raised 2025 midpoint.","Closed $980M syndicated credit facility; repaid $581M Pharmakon term loan, expects annualized interest savings.","Signed supply/quality agreements with Hikma for authorized generics of Nucynta/Nucynta ER; AG Nucynta ER launch expected Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-001953","json":"https://secwatch.observer/filing/0001104659-26-001953.json","markdown":"https://secwatch.observer/filing/0001104659-26-001953.md","text":"https://secwatch.observer/filing/0001104659-26-001953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/0001104659-26-001953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/tm262493d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:10:38.919452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}